Literature DB >> 17380159

FOXP3 modifies the phenotypic and functional properties of regulatory T cells.

Daniel J Campbell1, Steven F Ziegler.   

Abstract

In the periphery, tolerance to self antigens is mainly mediated by the CD4(+)CD25(+)FOXP3(+) subset of regulatory T cells, which can suppress the activity of autoreactive T cells that have escaped deletion in the thymus. The essential role of the transcription factor FOXP3 (forkhead box P3) in the development and function of these regulatory T cells has been well documented. It is also clear that regulatory T cells and effector T cells respond differently to T-cell receptor stimulation. In this Opinion article, we propose that these differences in responses are mediated by FOXP3, and are manifested by alterations in biochemical signalling pathways, patterns of gene expression and the appearance of cell-surface homing receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380159     DOI: 10.1038/nri2061

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  97 in total

1.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

Review 2.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

3.  Lactobacillus casei regulates differentiation of Th17/Treg cells to reduce intestinal inflammation in mice.

Authors:  Kai Wang; Hao Dong; Yu Qi; Zhihua Pei; Shushuai Yi; Xiaojie Yang; Yanli Zhao; Fanxing Meng; Shouping Yu; Tiezhong Zhou; Guixue Hu
Journal:  Can J Vet Res       Date:  2017-04       Impact factor: 1.310

4.  Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

Authors:  Jennifer S Whangbo; Haesook T Kim; Sarah Nikiforow; John Koreth; Ana C Alho; Bryn Falahee; Soomin Kim; Katharine Dusenbury; Marie J Fields; Carol G Reynolds; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood Adv       Date:  2019-04-09

5.  Critical roles of lysosomal acid lipase in T cell development and function.

Authors:  Peng Qu; Hong Du; David S Wilkes; Cong Yan
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

6.  BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling.

Authors:  Barbara H Chaiyachati; Anant Jani; Yisong Wan; Haichang Huang; Richard Flavell; Tian Chi
Journal:  EMBO J       Date:  2013-01-15       Impact factor: 11.598

7.  Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner.

Authors:  Guoping Jiang; Horng-Ren Yang; Lianfu Wang; Gary M Wildey; John Fung; Shiguang Qian; Lina Lu
Journal:  Transplantation       Date:  2008-12-15       Impact factor: 4.939

8.  Profound loss of intestinal Tregs in acutely SIV-infected neonatal macaques.

Authors:  Xiaolei Wang; Huanbin Xu; Chanjuan Shen; Xavier Alvarez; David Liu; Bapi Pahar; Marion S Ratterree; Lara A Doyle-Meyers; Andrew A Lackner; Ronald S Veazey
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

9.  Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.

Authors:  Ping Liu; Ines Santisteban; Lauri M Burroughs; Hans D Ochs; Troy R Torgerson; Michael S Hershfield; David J Rawlings; Andrew M Scharenberg
Journal:  Clin Immunol       Date:  2008-10-25       Impact factor: 3.969

10.  CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Erin E West; Matthew H Willett; Martin F Britos; Matthew R Pipeling; Roy G Brower; Rubin M Tuder; John F McDyer; Landon S King
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.